Ionis Pharmaceuticals, Inc.
IONSNASDAQHealthcare● Active
$73.24
$-1.24(-1.66%)
Market Cap$12.1B
P/E Ratio—
52W High$86.74
52W Low$34.78
Ionis Pharmaceuticals, Inc. (IONS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IONS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.94B | $0.71B | $0.79B | $0.59B | $0.81B |
| Cost of Revenue | $0.02B | $0.01B | $0.01B | $0.01B | $0.01B |
| Gross Profit | $0.93B | $0.69B | $0.78B | $0.57B | $0.80B |
| Gross Margin %(computed) | 98.31% | 98.41% | 98.84% | 97.60% | 98.66% |
| Operating Expenses | |||||
| R&D Expenses | $0.92B | $0.90B | $0.90B | $0.83B | $0.64B |
| G&A Expenses | $0.00B | $0.27B | $0.23B | $0.15B | $0.17B |
| Total Operating Expenses | $1.31B | $1.17B | $1.13B | $0.98B | $0.83B |
| Operating Income | ($0.38B) | ($0.48B) | ($0.35B) | ($0.41B) | ($0.03B) |
| Operating Margin %(computed) | -40.47% | -67.37% | -44.91% | -69.84% | -3.72% |
| Interest Income | $0.00B | $0.11B | $0.09B | $0.03B | $0.01B |
| Interest Expense | $0.07B | $0.09B | $0.08B | $0.01B | $0.01B |
| Income Before Tax | ($0.38B) | ($0.46B) | ($0.33B) | ($0.26B) | ($0.03B) |
| Income Tax Expense | $0.00B | ($0.01B) | $0.03B | $0.01B | ($0.00B) |
| Net Income | ($0.38B) | ($0.45B) | ($0.37B) | ($0.27B) | ($0.03B) |
| Net Margin %(computed) | -40.36% | -64.37% | -46.50% | -45.92% | -3.53% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
| Wtd Avg Shares | 0.16B | 0.15B | 0.14B | 0.14B | 0.14B |
| EBITDA | ($0.29B) | ($0.35B) | ($0.24B) | ($0.23B) | ($0.01B) |
| EBITDA Margin %(computed) | -30.38% | -50.16% | -29.95% | -38.78% | -0.64% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Ionis Pharmaceuticals, Inc. data
About Ionis Pharmaceuticals, Inc. (IONS) Income Statement
Ionis Pharmaceuticals, Inc. (IONS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IONS reported revenue of $0.94B, gross profit of $0.93B (gross margin 98.31%), and net income of ($0.38B) — a net profit margin of -40.36%.
Frequently asked questions
IONS · 4 questionsIonis Pharmaceuticals, Inc. (IONS) reported revenue of $0.94B for 2025, up 33.9% year-over-year.
IONS revenueIONS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08